Article

The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing

Medical and Scientific Affairs, MedImmune, LLC, One MedImmune Way, Gaithersburg, MD, 20878, USA, .
European Journal of Clinical Microbiology (Impact Factor: 2.67). 03/2012; 31(10):2549-57. DOI: 10.1007/s10096-012-1595-9
Source: PubMed

ABSTRACT In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2-17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in children with asthma aged 6-17 years have been demonstrated. However, few data are available for children younger than 6 years of age with asthma or prior wheezing. Safety and efficacy data were collected for children aged 2-5 years with asthma or prior wheezing from two randomized, multinational trials of LAIV and TIV (N = 1,940). Wheezing, lower respiratory illness, and hospitalization were not significantly increased among children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed among LAIV recipients (p < 0.05). Relative efficacies were consistent with the results observed in the overall study populations, which demonstrated fewer cases of culture-confirmed influenza illness in LAIV compared with TIV recipients. Study results support the safety and efficacy of LAIV among children aged 2-17 years with mild to moderate asthma or a history of wheezing. Data regarding LAIV use are limited among individuals with severe asthma or active wheezing within the 7 days before vaccination.

Download full-text

Full-text

Available from: Robert B Belshe, May 04, 2014
0 Followers
 · 
107 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut haben das Ziel, Infektionskrankheiten und damit assoziierte Komplikationen, die für das öffentliche Gesundheitswesen von Bedeutung (,,von öffentlichem Interesse“) sind, durch populationsbezogene Impfprogramme zu verhindern. Darüber hinaus enthalten die STIKO-Empfehlungen Hinweise für Indikationsimpfungen bei besonderer Gefährdungslage und umfassende Informationen zur Durchführung von Nachholimpfungen. Im vorliegenden Beitrag werden die Grundlagen der Impfpraxis sowie die aktuellen Empfehlungen der STIKO mit den wichtigsten Neuerungen beschrieben.
    Monatsschrift Kinderheilkunde 06/2013; 161(12). DOI:10.1007/s00112-013-2919-2 · 0.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: On January 24-26, 2013, the World Health Organization convened the first integrated meeting on "The development and clinical trials of vaccines that induce broadly protective and long-lasting immune responses" to review the current status of development and clinical evaluation of novel influenza vaccines as well as strategies to produce and deliver vaccines in novel ways. Special attention was given to the development of possible universal influenza vaccines. Other topics that were addressed included an update on clinical trials of pandemic and seasonal influenza vaccines in high-risk groups and vaccine safety, as well as regulatory issues.
    Vaccine 06/2013; 31(37). DOI:10.1016/j.vaccine.2013.06.047 · 3.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Seasonal influenza infections cause a high burden of disease for the whole community every year. Effective vaccines are available and used worldwide in adults and children. Discussion is ongoing as to whether influenza vaccination for children should be implemented in the National Immunization Program (NIP). Is there enough evidence to support routine influenza vaccination in children? In this review we briefly discuss the influenza viruses and the available vaccines. Subsequently, the current data available on influenza vaccination is reviewed and weighed against the Dutch criteria for the introduction of new vaccines into the NIP.
    The Journal of infection 10/2013; DOI:10.1016/j.jinf.2013.09.019 · 4.02 Impact Factor
Show more